While the European Union is raising its tone in the face of delivery delays announced by AstraZeneca, lab CEO Pascal Soriot refuses to turn a profit on 27’s back.

AstraZeneca, the British pharmaceutical company, is stuck in Europe against delays in the delivery of its vaccine against Kovid-19, “certainly not taking vaccines from Europeans to sell them elsewhere at a profit”, its CEO Pascal Soriot According to.

In an interview published on Tuesday on the daily website, the French leader said, “It would make no sense.” Le Figaro, Recalling that the laboratory, which partners with the University of Oxford, is not committed to making a profit on the sale of vaccines during the epidemic.

Brussels raised its tone on Monday against AstraZeneca, rejecting delays in the delivery of its Kovid-19 vaccine “unacceptable”, and now calls for “transparency” on exports outside the EU to be produced there. Pascal Soriot claims that the UK supply chain had some start-up issues, but “the UK contract was signed three months before the EU contract. So we have three more to resolve the issues with the UK” Months were. Problems encountered. ” .

17% of its production was delivered to Europe in February

While the EU regulatory green light for this vaccine is expected on Friday, the British lab announced last week that deliveries would be lower than expected in the first quarter due to a “drop in yield” at the European manufacturing site. European Union countries have already set aside what alarmed the shore after difficulties in delivery of the Pfizer-BioNTech vaccine, and reinforced pressure on the European Commission, which negotiated a pre-order contract on behalf of Twenty-Seven.

These relate to up to 400 million doses of the AstraZeneca / Oxford vaccine, which has the advantage of being easier to store and transport, as well as being cheaper to produce than its rivals. “I think Europe’s population is very stressed and tired of this epidemic that has lasted for a year. Governments are under pressure”, added Pascal Soriot in this interview, specifying that Europe “which is 5% of the world Represents the population, will receive. ” 17% of our production in February ”.